Therapy of small cell lung cancer: A perspective on two decades of clinical research

Seminars in Oncology

Volumn 15, Issue 3, 1988, Pages 278-299

  Seifter, Eric J ^a,b   Ihde, Daniel C ^a,b  

^a NATIONAL NAVAL MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

COMBINATION CHEMOTHERAPY; HUMAN; LUNG SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; RADIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMAN; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT CARE PLANNING; RADIOTHERAPY DOSAGE;

EID: 0023933689     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (199)

1. Small cell bronchogenic carcinoma: A distinct clinicopathologic entity
2. Small cell lung cancer 1973–1983: Early progress and recent obstacles
3. Keynote address on biostatistics and data retrieval
4. Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma
5. Staging and prognostic factors in small cell carcinoma of the lung
6. Problems in morphology and behavior of bronchopulmonary malignant diseases
7. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer
8. Clinical biology of small cell bronchogenic carcinoma: Relationship to surgical therapy
9. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten year follow-up
10. Alkylating agents in bronchogenic carcinoma
11. Lung cancer: Clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide
12. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung
13. Role of chemotherapy in small cell lung cancer: A consensus report of the International Association for the Study of Lung Cancer Workshop
14. Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination
15. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy
16. Small cell carcinoma of the lung: Combined chemotherapy and radiation
17. Current status of therapy for small cell carcinoma of the lung
18. Treatment of bronchogenic carcinoma II. Small cell
19. The influence of myelosuppression on the response to chemotherapy in small cell bronchogenic carcinoma
20. New drug development
21. Cisplatin plus VP-16 in small cell lung cancer
22. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer
23. Etoposide (VP-16) in the treatment of lung cancer
24. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma
25. Multicenter phase II trial of etoposide in previously treated small cell carcinoma of the lung
26. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer
27. Phase II trial of etoposide in previously treated small cell carcinoma of the lung
28. Etoposide in small cell lung cancer resistant to prior chemotherapy
29. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: A Southeastern Cancer Study Group trial
30. Phase II study of teniposide in small cell carcinoma of the lung
31. Teniposide (VM-26), an overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients
32. Commentary: Advances in small cell bronchogenic carcinoma
33. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung
34. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma
35. Small cell carcinoma of the lung: therapeutic management
36. Intensive chemotherapy of small cell bronchogenic carcinoma
37. Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung
38. A comparison between a single-agent short-course chemotherapy regimen and a quadruple prolonged course regimen for small cell bronchogenic carcinoma of limited extent
39. High-dose cyclophosphamide in small cell carcinoma of the lung
40. Small cell bronchogenic carcinoma: A review of therapeutic results
41. Combination chemotherapy of advanced lung cancer. A randomized trial
42. Chemotherapy of advanced small cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination
43. Cytoxan, etoposide, vincristine versus cytoxan, adriamycin, vincristine versus cytoxan, vincristine in the treatment of small cell lung cancer
44. Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung
45. Longterm results in combined modality treatment of small cell carcinoma of the lung
46. Small cell lung cancer Complete remission and improved survival
47. Combined modality treatment of extensive small cell lung cancer: A Southwest Oncology Group study
48. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer A Southwest Oncology Group study
49. Chemotherapy ν chemoimmunotherapy for small cell undifferentiated carcinoma of the lung
50. Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small cell carcinoma of the lung
51. Cytoxan, adriamycin, etoposide versus cytoxan, adriamycin, vincristine in the treatment of small cell lung cancer
52. VP-16-213 in combination chemotherapy with chest irradiation for small cell lung cancer: A randomized trial of the Piedmont Oncology Association
53. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer
54. Small cell lung cancer: A 10 year perspective
55. Combination chemotherapy in small cell lung carcinoma: A randomized study of two intensive regimens
56. Cisdichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice
57. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern Cancer Study Group trial
58. Cisplatin and etoposide chemotherapy for refractory small cell carcinoma of the lung
59. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer
60. Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small cell lung cancer
61. Etoposide (VP-16) and cisplatinum in previously treated small cell lung cancer: Clinical trial and in vitro correlates
62. cis-Dichlorodiammineplatinum (II) and VP-16-213: An active induction regimen for small cell carcinoma of the lung
63. VP-16 and cisplatin as first-line therapy for small cell lung cancer
64. Initial therapy with cisplatin plus VP-16 in small cell lung cancer
65. Randomized trial of high dose versus standard dose etoposide and cisplatin in extensive stage small cell lung cancer
66. Outpatient administration of VP-16 and cisplatin
67. Small cell lung cancer: Analysis of treatment factors contributing to prolonged survival
68. Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer
69. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial
70. Chemotherapy for small cell lung cancer (SCLC): A randomized study of maintenance therapy with cyclophosphamide, adriamycin, and vincristine (CAV) after remission induction with cisplatinum (cis DDP), VP-16-213 and radiotherapy
71. EORTC 08825: Induction versus induction plus maintenance chemotherapy (CT) in small cell lung cancer
72. Maintenance chemotherapy versus no maintenance chemotherapy in complete responders following induction chemotherapy in extensive disease (ED) small cell lung cancer (SCLC)
73. The second workshop on small cell carcinoma of the lung
74. Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited stage small cell carcinoma of the lung
75. The cellular heterogeneity of malignant neoplasms: Implications
76. Overreplication and recombination of DNA in higher eukaryotes: Potential consequences and biological implications
77. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate
78. Genetic origin of drug resistance in neoplasms
79. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma
80. Combination chemotherapy for small cell carcinoma of the lung: Continuous ν alternating non-cross-resistant combinations
81. Continuous ν alternating combination chemotherapy for advanced small cell carcinoma of the lung
82. Cyclic alternating non-cross-resistant chemotherapy in the management of small cell anaplastic carcinoma of the lung
83. Chemotherapy of small cell carcinoma of the lung: A randomized comparison of alternating and sequential combination chemotherapy programs
84. Intensive alternating chemotherapy regimen in small cell carcinoma of the lung
85. Cyclic alternating chemotherapy for small cell carcinoma of the lung
86. A randomized comparison of conventional chemotherapy with immediate alternation of non-cross-resistant chemotherapy in extensive disease (ED) small cell lung cancer (SCLC)
87. Intensive induction chemotherapy with cisplatin plus etoposide with radiotherapy for small cell lung cancer
88. Combination cyclophosphamide, adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer
89. The use of VP-16 plus cisplatin during induction chemotherapy for small cell lung cancer
90. Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect
91. Dose: A critical factor in cancer chemotherapy
92. Cotrimoxazole prophylaxis during high-dose chemotherapy of small cell lung cancer
93. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung
94. High-dose cyclophosphamide (C) in the induction (IND) chemotherapy (CT) of small cell lung cancer (SCLC)—minor improvements in rate of remission and survival
95. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer
96. Combination chemotherapy using high-dose or low-dose methotrexate for small cell carcinoma of the lung-a randomized trial
97. Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung
98. Treatment of extensive stage small cell bronchogenic carcinoma: Effects of variation in intensity of induction chemotherapy
99. Extensive stage small-cell bronchogenic carcinoma: Intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide
100. Effects of intensive induction chemotherapy for extensive-disease small-cell bronchogenic carcinoma in protected-environment-prophylactic antibiotic units
101. High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma
102. High dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive stage small cell lung cancer
103. Implications of kinetic heterogeneity in clinical oncology
104. Cisplatin, Adriamycin, and etoposide for remission induction of small cell bronchogenic carcinoma: Evaluation of efficacy and toxicity and pilot study of a late intensification with autologous bone marrow rescue
105. Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung
106. High-dose cyclophosphamide and VP-16 as late dosage intensification therapy for small cell carcinoma of the lung
107. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma
108. Late intensification in small cell lung cancer: A Phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation
109. High-dose intensification therapy with autologous bone marrow support for limited small cell bronchogenic carcinoma
110. Late intensive combined modality therapy followed by autologus bone marrow infusion in extensive-stage small cell lung cancer
111. Late intensification with autologous bone marrow transplantation for small cell lung cancer: A randomized trial
112. High-dose melphalan as consolidation therapy for good prognosis patients with small cell carcinoma of bronchus
113. Small cell lung cancer: Whither late intensification?
114. Combination chemotherapy with or without concurrent thoracic radiotherapy in limited stage small cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group
115. Late consolidation with cisplatin plus VP-16 following induction chemotherapy with cyclophosphamide, adriamycin, and vincristine in limited small cell lung cancer: A Southeastern Cancer Study Group random prospective study
116. Salvage radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy
117. Small cell carcinoma of the lung: Reinduction therapy after late relapse
118. New drugs in small cell lung cancer
119. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: A randomized prospective study by the Southeastern Cancer Study Group
120. Combined modality treatment of regional small cell undifferentiated carcinoma of the lung: A cooperative study of the RTOG and ECOG
121. Is thoracic radiation necessary for patients with limited stage small cell lung cancer?
122. The state of the art toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma
123. The role of radiation therapy in the treatment of small cell lung cancer
124. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: A prospective randomized trial
125. Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung
126. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report
127. A randomized study: Small cell anaplastic lung cancer treated by combined chemotherapy and adjuvant radiotherapy
128. Current status of research into small cell carcinoma of the lung: Summary of the Second Workshop of the International Association for the Study of Lung Cancer (IASLC)
129. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years of follow-up
130. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: A controlled trial
131. Multimodal therapy for limited small cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with widefield versus reduced volume radiation in partial responders
132. The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the lung
133. Pulmonary toxicity with combined modality therapy for limited stage small cell lung cancer
134. Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease
135. Influence of chest radiotherapy in frequency and patterns of chest relapse in disseminated small cell lung carcinoma: A Southwest Oncology Group study
136. Small cell anaplastic carcinoma of the lung: The Cancer and Leukemia Group B experience
137. Combined modality treatment for oat cell carcinoma of the lung: A randomized trial
138. Comparison of chemotherapy alone versus chemotherapy and radiation therapy of extensive small cell carcinoma of the lung
139. Hemibody radiation, an active therapeutic modality for the management of patients with small cell lung cancer
140. Preliminary report on “one-time” and high-dose irradiation of the upper and lower half-body in patients with small cell lung cancer
141. Half-body and local chest irradiation as consolidation following response to standard induction chemotherapy for disseminated small cell lung cancer: An ECOG pilot report
142. Upper hemibody and local chest irradiation as consolidation following response to high-dose induction chemotherapy for small cell bronchogenic carcinoma—a pilot study
143. Radiation as a non—cross-resistant systemic agent: Experience with hemibody and total-body irradiation in patients with small-cell lung cancer
144. Total-body irradiation in oat cell carcinoma of the bronchus
145. Total body irradiation vs. chemotherapy as a systemic adjuvant for small cell carcinoma of the lung
146. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma: A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy
147. Brain metastases in small cell carcinoma of the lung
148. Results of whole-brain irradiation for metastases from small cell carcinoma of the lung
149. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation
150. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer: Potential benefit restricted to patients in complete response
151. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival
152. Changes in the relative risk and sites of central nervous system metastasis with effective combined chemotherapy and radiation therapy for small cell carcinoma of the lung
153. Intracranial metastases in small cell carcinoma of the lung: Correlation of clinical and autopsy findings
154. Role of radiation therapy in small cell anaplastic carcinoma of the lung
155. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma
156. Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung
157. Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy
158. Therapeutic cranial radiotherapy (RT) for brain metastases in small cell lung cancer
159. Small cell carcinoma of the lung: Attempt to remedy cause of the past therapeutic failure
160. Follow-up neurological evaluation in patients with small cell carcinoma treated with prophylactic cranial irradiation and chemotherapy
161. Long-term survival and toxicity in small cell lung cancer: Southwest Oncology Group Study
162. Morbidity in long-term survivors of small cell carcinoma of lung
163. Prospective evaluation of changes in computed cranial tomography in patients with small cell lung carcinoma treated with chemotherapy and prophylactic cranial irradiation
164. Disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung cancer
165. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2 to 10 year survivors of small-cell lung cancer
166. Neurotoxicity in long-term survivors of small cell lung cancer
167. The solitary pulmonary nodule: Ten year follow-up of Veterans Administration-Armed Forces Cooperative study
168. Survival after resection of small cell carcinoma of the bronchus
169. Adverse prognostic effect of N2 disease in treated small cell carcinoma of the lung
170. Effect of histologically verified TNM stage on disease control in treated small cell carcinoma of the lung
171. Surgical resection in the management of small cell carcinoma of the lung
172. Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer
173. Effect of initial resection of small cell carcinoma of the lung. A review of Southwest Oncology Group study 7628
174. Long-term survival in small cell carcinoma of the lung: A population experience
175. Treatment policy of surgery in small cell carcinoma of the lung: Retrospective analysis of a series of 874 consecutive patients
176. Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer A study of 150 operable patients
177. Longterm survival in limited-stage small cell lung carcinoma. Experience in Rochester, New York from 1975 to 1981
178. Very limited small cell lung cancer: Results of non-surgical treatment
179. The feasibility of adjuvant surgery in limited-stage small cell carcinoma: A prospective evaluation
180. The role of surgery in small cell undifferentiated lung cancer (SCLC)
181. Prospective evaluation of adjuvant surgical resection in small cell lung cancer
182. The role of surgery in the management of selected patients with small cell carcinoma of the lung
183. Is there a role for surgery after chemotherapy in limited small cell lung cancer (SCLC)?
184. Changes in morphologic and biochemical characteristics of small cell carcinoma of the lung A clinico-pathologic study
185. Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients
186. Effects of therapy on the morphology and behavior of small cell carcinoma of the lung: A clinicopathologic study
187. A prospective study of combined modality therapy including surgery for limited small cell lung cancer
188. Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma
189. Long-term survivors of small cell carcinoma of the lung
190. Patients with small cell lung cancer treated with combination chemotherapy with or without irradiation: Data on potential cures, chronic toxicities, and late relapses after a 5 year to 11 year follow-up
191. A 10 year experience with combined modality therapy for stage III small cell lung carcinoma
192. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer
193. Longterm disease free survival in small cell carcinoma of the lung: A study of clinical determinants
194. Second primary bronchogenic carcinomas after small cell carcinoma: Report of two cases and review of the literature
195. Nonsmall cell lung cancer: Major cause of late mortality in patients with small cell lung cancer
196. Acute leukemia following intensive therapy for small cell carcinoma of the lung
197. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung
198. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung
199. Acute nonlymphocytic leukemia after treatment of small cell lung cancer